Maternal antiretroviral therapy in breast-fed HIV-exposed children

Maternal antiretroviral therapy in breast-fed HIV-exposed children - MARVIN

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029318

Enrollment

100

Registered

2022-07-04

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z20.6

Interventions

Group 1: HIV-exposed, breastfed Group 2: HIV-exposed, formula-fed

Eligibility

Sex/Gender

All

Age

0 Days to 18 Years

Inclusion criteria

Inclusion criteria: HIV exposed

Exclusion criteria

Exclusion criteria: HIV infection

Design outcomes

Primary

Measure	Time frame
Are relevant quantities of the medicines transmitted through breast milk present in the breastfed children? When? ongoing measurement during breastfeeding/follow-up after HIV exposure What? drug levels. How? routine blood collection	—

Secondary

Measure	Time frame
Are there differences in laboratory parameters (e.g. cytopenia, elevated transaminases, hyperbilirubinemia) or clinical parameters (e.g. weight development, growth in height) between breastfed and non-breastfed HIV-exposed children? When? continuous measurement during follow-up What? Blood count, laboratory parameters How? routine blood collection	—

Countries

Germany

Contacts

Public ContactBenedikt Spielberger

Zentrum für Kinder- und Jugendmedizin, Uniklinik Freiburg

benedikt.spielberger@uniklinik-freiburg.de0049 761 27045294

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026